Not sure on the downgrade piece, I might've missed something? MLA does suffers from liquidity (as shown by the +/- 20% daily SP movements) as there is a fair bit tied up by the top-20 holders. But all balance sheet metrics are pointing to a company producing solid growth profitably, I believe this year is the breakout year, and realistically could be seeing a share price of 8-10c by year end IMO.
The half year report also outlined prospects of several products hitting MLA's range which should see a bumper start to the next FY.
"User trials for a number of products, including DualCap®, AirQ and the Ardo range of breast pumps, are currently underway. Successful completion of these trials should see sales in the latter half of fiscal 2017"
all IMO, DYOR etc...
MLA Price at posting:
6.7¢ Sentiment: Buy Disclosure: Held
